Plain Language Summary {#Sec1}
======================

Tumor necrosis factor (TNF) inhibitors are biologic therapies used for the treatment of several chronic inflammatory diseases. Biosimilars are biologics that are very similar to an approved biologic therapy (called an "originator") in terms of quality, clinical efficacy, and safety. Among patients taking TNF-inhibitor therapy, the availability of biosimilars has now made it possible to switch between TNF-inhibitor originators and corresponding biosimilars for economic or other non-medical reasons. However, the potential clinical consequences of non-medical switching remain largely unknown, since much of the evidence comes from studies that were not adequately designed to evaluate efficacy or safety after switching therapies. To evaluate the consequences of non-medical switching from an originator to its biosimilar, we propose seven key study design elements that should be considered when assessing the evidence. This article used these design elements to assess the strength and consistency of the current non-medical switching evidence, with a focus on studies evaluating TNF inhibitors. A comprehensive literature search identified 98 publications (91 studies) describing non-medical switching from a TNF-inhibitor originator to its biosimilar. None of these non-medical switching studies were found to use all seven key design elements, and the data from these studies were inconsistent and inconclusive, suggesting that the current evidence for non-medical switching may be weak. Therefore, patients should not be indiscriminately switched from an originator TNF inhibitor to its biosimilar for non-medical reasons. Decisions to switch therapies should remain between treating physicians and patients, be made on a case-by-case basis, and rely upon robust scientific evidence.

Introduction {#Sec2}
============

Tumor necrosis factor (TNF) inhibitors are widely used biologics employed in the treatment of immune-mediated inflammatory diseases (IMIDs) such as rheumatoid arthritis (RA), inflammatory bowel disease (IBD), and psoriasis (Ps) \[[@CR1]\]. The launch of anti-TNF biosimilars is expected to provide cost savings and add to the economic sustainability of the healthcare system \[[@CR2], [@CR3]\]. Consequently, some payers and formulary decision makers in certain geographic regions are supporting practice of non-medical switching between originator products and their biosimilars \[[@CR2]--[@CR4]\]. Non-medical switching occurs when a patient whose current therapy is effective and well tolerated is switched between therapies, such as from an originator TNF inhibitor to its biosimilar, for economic or other non-medical reasons \[[@CR3], [@CR5], [@CR6]\].

A biosimilar is a biologic product approved based on the totality of evidence demonstrating that it is highly similar to an approved biologic product (called the "originator" or "reference product") in terms of quality (i.e., physicochemical and biologic properties) and clinical efficacy and safety \[[@CR7], [@CR8]\]. Because biosimilars have many specific and unique considerations related to regulatory approval, specific guidelines for biosimilars have been developed by relevant authorities such as the European Medicines Agency (EMA), US Food and Drug Administration (FDA), and World Health Organization (WHO; Table [1](#Tab1){ref-type="table"}) \[[@CR7]--[@CR9]\]. Although the various guidelines differ somewhat, all suggest a step-wise approach to demonstrate biosimilarity with an originator.Table 1Definitions of biosimilarityAgencyDefinitionEMA \[[@CR7]\]A biologic medicinal product that contains a version of the active substance of an already authorized original biologic medicinal productFDA \[[@CR8]\]A biologic product that is highly similar to the originator product, notwithstanding minor differences in clinically inactive components, and with no clinically meaningful differences between the biologic product and the reference product in terms of safety, purity, and potencyWHO \[[@CR9]\]A biotherapeutic product that is similar in terms of quality, safety, and efficacy to an already licensed reference biotherapeutic product*EMA* European Medicines Agency, *FDA* US Food and Drug Administration, *WHO* World Health Organization

In the USA, a biosimilar can also receive a further designation of interchangeability. An interchangeable product is required to meet additional requirements that go beyond biosimilarity to demonstrate that it is expected to produce the same clinical result as the originator product in any given patient and, for products that are administered more than once, that no risks exist in terms of safety or decreased efficacy when alternating or switching between the originator and biosimilar products \[[@CR10]\]. To date, no biosimilar has been designated as interchangeable \[[@CR11]\]. Although the FDA designation of interchangeability provides assurance that a product is safe for substitution, individual US states are expected to legislate their own policies on automatic substitution \[[@CR12]\]. In contrast, the EMA has no remit to formally designate two products as interchangeable and instead allows each member country to determine its own policies \[[@CR13]\].

As mentioned above, the launch of biosimilars has introduced the possibility for non-medical switching between originator biologic products and their biosimilars, and this process has already been adopted or is being evaluated in several countries \[[@CR14]--[@CR17]\]. However, to properly evaluate the safety and efficacy of non-medical switching between an originator product and its biosimilar, we propose seven key study design elements that should be considered when assessing the existing evidence (Table [2](#Tab2){ref-type="table"}). Comprehensive non-medical switching studies should be (1) randomized and double-blind, (2) adequately controlled, and (3) adequately powered with (4) multiple switching, including (5) an assessment of immunogenicity and (6) an adequate follow-up, and (7) report individual patient-level outcomes \[[@CR3], [@CR18]--[@CR20]\]. The importance of each key study design element is detailed in Table [2](#Tab2){ref-type="table"}. These elements are derived from the key evidentiary standards for an interchangeable product as per the definition adopted by the FDA \[[@CR10]\].Table 2Design elements for a switching study \[[@CR3], [@CR10], [@CR18]--[@CR20]\]ElementReasonRandomized, double-blind trialEnsures comparison between homogenous populations and reduces/controls biasAdequately controlledAllows the measurement of the impact of a single intervention that differs between study armsAdequately poweredAllows for statistically supported inference of outcomes to the universe represented in the study populationMultiple switchesMay elicit a prime boost response when the subject is exposed to different sets of epitopes (antigenic determinants)Immunogenicity-related outcomesPotential pathophysiologic and clinical response to "prime boost" effect from alternationAdequate follow-upAllows for the detection of late-onset, low-frequency immunogenicityIndividual patient-level outcomesAllows for the study to apply to "any given patient"For a non-medical switching study, switching is defined as when a prescriber exchanges one medicine for another medicine with the same therapeutic intent \[[@CR123]\]. In contrast, automatic substitution is the practice of dispensing one medicine in place of another equivalent and interchangeable medicine at the pharmacy level (also known as pharmacy-level substitution) without consulting the prescriber \[[@CR124]\]

As of 14 February 2018, nine TNF inhibitor biosimilars have been approved by the EMA \[[@CR21]\] and six by the FDA \[[@CR11]\] (Table S1). Since their approval, numerous non-medical switching studies have been conducted with the intent to demonstrate safety and efficacy of switching from an originator to its biosimilar. However, these studies vary greatly not only in their study designs, but also in their results. The objective of this systematic review was to assess the robustness and conclusiveness of the current evidence on non-medical switching from an originator to its biosimilar with a focus on TNF inhibitors. All identified randomized controlled trials (RCTs) and real-world evidence (RWE) studies were assessed for (1) robustness of data, based on whether they fulfilled the seven key study design elements described above, and (2) consistency of the evidence across studies while considering the heterogeneity of the studies.

Methods {#Sec3}
=======

This systematic literature review searched the following databases: BIOSIS Previews^®^, Derwent Drug File, Embase^®^, International Pharmaceutical Abstracts, MEDLINE^®^, and SciSearch^®^. The initial search was performed on 10 November 2017, with an updated search performed on 14 February 2018. Search terms included the following: biosimilar or biogeneric or "subsequent entry biologic" or "follow on biologic" or "GP 2015" or "CT P13" or SB2 OR SB4 or Remsima or Flixabi or Benepali or Brenzys or Inflectra; interchange\* or switch\* or transition\* or substitute\* or exchang\* or replac\* or crossover or alternat\* or conversion or convert\*; nocebo or "non immunogenic\*" or nonimmunogenic\* or nonmedical or "non medical"; humira or adalimumab or remicade or infliximab or Enbrel or etanercept or simponi or golimumab or cimzia or certolizumab; "tum\*r necrosis factor blocker" or "tnf alpha blockade" or "anti tnf agent\*". Full search terms and strategy are listed in Table S2. The search was limited to English language, humans and publication dates from 1 January 2012 to 14 February 2018.

All search results were manually screened by two reviewers for eligibility and to exclude duplicates and ineligible studies (Fig. [1](#Fig1){ref-type="fig"}). Full texts of all identified publications were further manually screened, and only studies that reported switching from an originator TNF inhibitor to its biosimilar were included. A congress abstract was excluded if the included data had been published in a full-length article by 14 February 2018. Bibliographies of the identified studies were also manually searched for additional publications that fit the eligibility criteria but had not been detected by the original search. The characteristics and design elements of each identified study were assessed and compared with the seven design elements of a robust switching study (Table [2](#Tab2){ref-type="table"}). In addition, patient discontinuation rates from each study were collected to assess the consistency of evidence across studies while taking into consideration the heterogeneity of the studies.Fig. 1Flow diagram for the selection of studies. *NMS* non-medical switching

For this publication, individual patient-level data were defined as individual data points that included, but were not limited to, immunogenicity markers that were separately reported for each individual participant in the publication of a clinical study; data reported separately for each individual study participant may also have included, for example, demographic characteristics, efficacy outcomes, and/or laboratory test results. This article is based on previously conducted studies and does not contain any studies with human participants or animals performed by any of the authors.

Results {#Sec4}
=======

The search identified 603 publications (Fig. [1](#Fig1){ref-type="fig"}). Eight duplicate records were excluded, and eight publications were identified through other sources. The resulting 603 publications were manually screened for eligibility, of which 426 publications did not meet the inclusion criteria and were excluded. The full articles or congress abstracts of the remaining 177 publications were manually reviewed to identify studies that reported switching from an originator TNF inhibitor to its biosimilar. Of these, 79 were excluded (reasons: congress abstract had been published as a full article, *n* = 36; did not report non-medical switching data, *n* = 23; not relevant or more recent data are available from the study, *n* = 19; case study, *n* = 1), and the remaining 98 publications (corresponding to 91 studies) were included in this review (Fig. [1](#Fig1){ref-type="fig"}) \[[@CR14]--[@CR17], [@CR22]--[@CR115]\].

Randomized Controlled Trials {#Sec5}
----------------------------

A total of 17 RCTs (20 publications) were included (Table [3](#Tab3){ref-type="table"}) \[[@CR16], [@CR22]--[@CR40]\], of which 10 (59%) were in rheumatology, 4 (24%) in dermatology, 2 (12%) in gastroenterology, and 1 (6%) in multiple indications (Fig. [2](#Fig2){ref-type="fig"}a). Eight (47%) studies investigated a switch from originator infliximab to its biosimilar (CT-P13, SB2, or BOW015), seven (41%) studies from originator adalimumab to its biosimilar (ABP 501, SB5, BI 695501, GP2017, FKB327, or CHS-1420), and two (12%) studies from originator etanercept to its biosimilar (SB4 or GP2015). Follow-up durations post switch ranged from 8 to 105 weeks (Fig. [3](#Fig3){ref-type="fig"}a). All studies included a comparison group, which, in 11 (65%) studies, consisted of randomized patients continuing treatment with the originator; in the remaining 6 (35%) studies, the control group consisted of biosimilar continuers.Table 3Summary of randomized controlled switching or transition trialsStudyBiosimilar (study name)PopulationSwitch groupControl groupFollow-up duration post switchDiscontinuation rate (switch vs. control group)Dose escalation allowedAdalimumab biosimilars Blauvelt et al. 2017 \[[@CR22]\]GP2017 (ADACCESS)PsOriginator to GP2017 (*n* = 63)Originator continuers (*n* = 127)^a^34 weeks16 (25%) vs. 23 (18%)^a^NR Cohen et al. 2017 \[[@CR23]\]BI 695501 (VOLTAIRE-RA)RAOriginator to BI 695501 (*n* = 147)Originator continuers (*n* = 148)^b^24--34 weeks9 (6%) vs. 8 (5%)^b^NR Cohen et al. 2016 \[[@CR24]\]ABP 501RAOriginator to ABP 501 (*n* = 237)ABP 501 continuers (*n* = 229)46 weeks30 (13%) vs. 25 (11%)^c^NR Genovese et al. 2017 \[[@CR25]\]FKB327 (ARABESC-OLE)RAOriginator to FKB327 (*n* = 108)Originator continuers (*n* = 213)^d^76 weeksNRNR Hodge et al. 2017 \[[@CR26]\]CHS-1420Ps and PsAOriginator to CHS-1420 (*n* = 124)Originator continuers (*n* = 129)^e^8 weeksNRNR Papp et al. 2017 \[[@CR27]\]ABP 501PsOriginator to ABP 501 (*n* = 77)Originator continuers (*n* = 79)^f^36 weeks9 (12%) vs. 8 (10%)NR Weinblatt et al. 2017 \[[@CR28], [@CR29]\]SB5RAOriginator to SB5 (*n* = 125)Originator continuers (*n* = 129)^g^28 weeks8 (6%) vs. 5 (4%)^g^NREtanercept biosimilars Emery et al. 2017 \[[@CR30]\]SB4RAOriginator to SB4 (*n* = 119)SB4 continuers (*n* = 126)48 weeks6 (5%) vs. 7 (6%)NR Griffiths et al. 2017 \[[@CR31], [@CR32]\]GP2015 (EGALITY)PsOriginator to GP2015 (*n* = 96)Originator continuers (*n* = 151)^h^40 weeks6 (6%) vs. 14 (9%)NRInfliximab biosimilars Jørgensen et al. 2017 \[[@CR16], [@CR33]\]CT-P13 (NOR-SWITCH)IMIDOriginator to CT-P13 (*n* = 240)^i^Originator continuers (*n* = 241)78 weeks18 (8%) vs. 25 (10%)^i^NR Kim et al. 2017 \[[@CR34]\]CT-P13CDOriginator to CT-P13 (*n* = 55)Originator continuers (*n* = 54)^j^24 weeksNRNR Park et al. 2017 \[[@CR35]\]CT-P13 (PLANETAS)ASOriginator to CT-P13 (*n* = 86)CT-P13 continuers (*n* = 88)48 weeks9 (10%) vs. 7 (8%)No Smolen et al. 2018 \[[@CR36]\]SB2RAOriginator to SB2 (*n* = 94)Originator continuers (*n* = 101)^k^16 weeks6 (6%) vs. 5 (5%)Yes Tanaka et al. 2017 \[[@CR37]\]CT-P13RAOriginator to CT-P13 (*n* = 33)CT-P13 continuers (*n* = 38)105 weeks11 (33%) vs. 6 (16%)Yes Taylor et al. 2016 \[[@CR38]\]BOW015RAOriginator to BOW015 (*n* = 53)BOW015 continuers (*n* = 104)38 weeksNRNo Volkers et al. 2017 \[[@CR39]\]CT-P13 (SIMILAR)IBDOriginator to CT-P13 (*n* = 15)Originator continuers (*n* = 6)30 weeksNRNR Yoo et al. 2017 \[[@CR40]\]CT-P13 (PLANETRA)RAOriginator to CT-P13 (*n* = 144)CT-P13 continuers (*n* = 158)48 weeks16 (11%) vs. 25 (16%)No*AS* ankylosing spondylitis, *IBD* inflammatory bowel disease, *IMID* immune-mediated inflammatory diseases, *NR* not reported, *Ps* psoriasis, *PsA* psoriatic arthritis, *RA* rheumatoid arthritis^a^Adalimumab originator to GP2017, *n *= 63; GP2017 to adalimumab originator, *n* = 63; originator continuers, *n* = 127; GP2017 continuers, *n* = 126; discontinuation rates available from results posted on ClinicalTrials.gov (NCT02016105)^b^Adalimumab originator to BI 695501, *n* = 147 (full-analysis set) or *n* = 146 (safety set); originator continuers, *n* = 148; BI 695501 continuers, *n* = 298; discontinuation rates available from results posted on ClinicalTrials.gov (NCT02137226)^c^Discontinuation rates available from results posted on ClinicalTrials.gov (NCT02114931)^d^Treatment groups from weeks 0 to 28 of open-label extension: originator to FKB327, *n* = 108; originator continuers, *n* = 213; FKB327 continuers, *n* = 216; FKB327 to originator, *n* = 108; thereafter, all patients received FKB327 to week 76^e^Adalimumab originator to CHS-1420, *n* = 124; originator continuers, *n* = 129; CHS-1420 continuers, *n* = 250^f^Adalimumab originator to ABP 501, *n* = 77; originator continuers, *n* = 79; ABP 501 continuers, *n* = 152^g^Adalimumab originator to SB5, *n* = 125; originator continuers, *n* = 129; SB5 continuers, *n* = 254; discontinuation rates available from results posted on ClinicalTrials.gov (NCT02167139)^h^Etanercept originator to GP2015, *n* = 96; originator continuers, *n* = 151; GP2015 continuers, *n* = 150; GP2015 to etanercept originator, *n* = 100; each switch group underwent a sequence of three treatment switches at 6-week intervals^i^One patient who had been randomized to switch from infliximab originator to biosimilar CT-P13 withdrew consent and did not receive treatment; this patient was counted in neither the switch group nor among those who discontinued from the switch group presumably because consent withdrawal preceded treatment administration. Reported discontinuation rates correspond to the end of the 52-week main study, not the 78-week extension study^j^Infliximab originator to CT-P13, *n* = 55; CT-P13 to infliximab originator, *n* = 55; originator continuers, *n* = 54; CT-P13 continuers, *n* = 56^k^Infliximab originator to SB2, *n *= 94; originator continuers, *n* = 101; SB2 continuers, *n* = 201 Fig. 2Summary of originators (inner ring), biosimilars (middle ring), and therapeutic areas (outer ring) investigated in published RCTs and RWE studies reporting non-medical switching of TNF inhibitor originator to biosimilar. *Derm* dermatologic diseases, *Gastro* gastroenterologic diseases, *Multiple* multiple indications, *NS* not specified, *RCT* randomized controlled trial, *Rheum* rheumatic diseases, *RWE* real-world evidence, *TNF* tumor necrosis factor. ^a^Etanercept-biosimilar and infliximab-biosimilar aspects of the De Cock et al. \[[@CR17]\] and Egeberg et al. \[[@CR44]\] studies are each counted separately Fig. 3Follow-up duration^a^ post switch reported in published RCTs and RWE studies reporting non-medical switching from TNF inhibitor originator to biosimilar. Proportions of studies with \< 12 and ≥ 12 months of follow-up are displayed within each graph. *RCT* randomized controlled trial; *RWE* real-world evidence; *TNF* tumor necrosis factor. ^a^For conversion of follow-up duration reported in months or years, conversion factors of 4.33 weeks/month and 52 weeks/year, respectively, were used. If a range of follow-up duration was provided, the maximum provided value was graphed. ^b^Of the 74 RWE studies, 65 reported follow-up duration. Etanercept-biosimilar and infliximab-biosimilar aspects of the De Cock et al. \[[@CR17]\] and Egeberg et al. \[[@CR44]\] studies are each displayed separately

Overall, none of the studies fulfilled all the design elements for a robust switching study (Table [4](#Tab4){ref-type="table"} and Fig. [4](#Fig4){ref-type="fig"}a). Only two (12%) studies (NOR-SWITCH \[[@CR16]\] and ARABESC-OLE \[[@CR25]\]) met five of the seven design elements, and three (18%) studies (ADACCESS \[[@CR22]\], EGALITY \[[@CR31], [@CR32]\], and ARABESC-OLE) included multiple switches. Furthermore, in all of the studies except NOR-SWITCH, ADACCESS, and EGALITY, the switching component was part of the extension periods. In the three-period ADACCESS and EGALITY studies, the multiple switching phase (period 2) was preceded by a two-arm, head-to-head period (at the end of which the primary end points were assessed) and, after the last switch between treatments, concluded with a follow-up period. The single-switch non-crossover NOR-SWITCH study was the only study powered to detect differences in the rate of disease worsening between the switch and control groups. However, because it assessed multiple indications, NOR-SWITCH was powered at a pooled, and not individual, indication level \[[@CR16]\]. None of the RCTs have reported individual patient-level outcomes, and only three (18%) RCTs included follow-up periods of ≥ 12 months' duration post switch (Table [4](#Tab4){ref-type="table"} and Fig. [4](#Fig4){ref-type="fig"}a).Table 4Characteristics and design elements of randomized controlled trialsStudyRandomized at time of switchControl group (originator continuers)Powered to detect differences in efficacy after switchMultiple switchImmunogenicity data reportedFollow-up ≥ 12 months after switchIndividual patient-level outcomes^a^ reportedAdalimumab biosimilars Blauvelt et al. 2017 \[[@CR22]\]YesYesNoYesYesNoNo Cohen et al. 2017 \[[@CR23]\]YesYesNo^b^NoYesNoNo Cohen et al. 2016 \[[@CR24], [@CR125]\]No^c^NoNo^b^NoYesNoNo Genovese et al. 2017 \[[@CR25]\]YesYesNRYesYesYesNo Hodge et al. 2017 \[[@CR26], [@CR126]\]Yes^d^YesNo^b^NoYesNoNo^e^ Papp et al. 2017 \[[@CR27], [@CR127]\]YesYesNo^b^NoYesNoNo^e^ Weinblatt et al. 2017 \[[@CR28], [@CR29]\]YesYesNo^b^NoYesNoNoEtanercept biosimilars Emery et al. 2017 \[[@CR30], [@CR128]\]No^c^NoNo^b^NoYesNoNo^e^ Griffiths et al. 2017 \[[@CR31], [@CR32]\]YesYesNo^b^YesYesNoNo^e^Infliximab biosimilars Jørgensen et al. 2017 \[[@CR16]\]YesYesYes^f^NoYesYesNo^e^ Kim et al. 2017 \[[@CR34]\]YesYesNoNoYesNoNo Park et al. 2017 \[[@CR35], [@CR129]\]No^c^NoNo^b^NoYesNoNo^e^ Smolen et al. 2018 \[[@CR36]\]YesYesNo^b^NoYesNoNo Tanaka et al. 2017 \[[@CR37], [@CR130]\]No^c^NoNoNoYesYesNo^e^ Taylor et al. 2016 \[[@CR38]\]No^c^NoNoNoNoNoNo Volkers et al. 2017 \[[@CR39]\]YesYesNoNoNoNoNo^e^ Yoo et al. 2017 \[[@CR40], [@CR131]\]No^c^NoNo^b^NoYesNoNo^ea^Individual patient-level data defined as individual data points that included, but were not limited to, immunogenicity markers that were separately reported for each individual participant in the publication of a clinical study; data reported separately for each individual study participant may also have included, for example, demographic characteristics, efficacy outcomes, and/or laboratory test results^b^Powered to detect differences in efficacy in pre-switch analysis^c^Study was an open-label extension of a randomized controlled study; patients remained blinded to their original treatment at the time of the switch^d^Randomization details available from study design as posted on ClinicalTrials.gov (NCT02489227)^e^Reports patient-reported outcome measures^f^Powered at pooled, but not at individual, indication level for disease worsening Fig. 4Fulfillment of the seven switching study design elements in published RCTs and RWE studies reporting non-medical switching from TNF inhibitor originator to biosimilar. *RCT* randomized controlled trial, *RWE* real-world evidence, *TNF* tumor necrosis factor. ^a^Etanercept-biosimilar and infliximab-biosimilar aspects of the De Cock et al. \[[@CR17]\] and Egeberg et al. \[[@CR44]\] studies are each counted separately. ^b^Refers only to originator continuers. ^c^Powered at pooled, but not at individual, indication level for disease worsening. ^d^Individual patient-level data defined as individual data points that included, but were not limited to, immunogenicity markers that were separately reported for each individual participant in the publication of a clinical study; data reported separately for each individual study participant may also have included, for example, demographic characteristics, efficacy outcomes, and/or laboratory test results. ^e^Excludes any comparison group consisting of naive patients or patients previously treated with other biologics

Real-World Evidence Studies {#Sec6}
---------------------------

A total of 74 RWE studies (78 publications) were included (Table [5](#Tab5){ref-type="table"}) \[[@CR14], [@CR15], [@CR17], [@CR41]--[@CR115]\], of which 36 (49%) were in gastroenterology, 30 (41%) in rheumatology, 4 (5%) in dermatology, and 4 (5%) in multiple indications (Fig. [2](#Fig2){ref-type="fig"}b). Most studies (*n* = 64; 86%) investigated a switch from infliximab originator to its biosimilar, and only 12 (16%) studies investigated a switch from etanercept to its biosimilar (percentages do not add to 100% because 2 studies each reported data for both infliximab and etanercept) \[[@CR17], [@CR44]\]. As of 14 February 2018, no published RWE studies have investigated a non-medical switch from adalimumab originator to its biosimilars, likely because no adalimumab biosimilars were commercially available as of that date. A historical comparison cohort or a parallel control group consisting of patients who had continued originator therapy was included in only 12 (16%) studies (Tables [5](#Tab5){ref-type="table"}, [6](#Tab6){ref-type="table"}), and 18 (24%) studies included a control group consisting of treatment-naive patients initiating biologic therapy with the biosimilar. Of the 72 studies that reported the number of patients who switched from originator to biosimilar, most (*n *= 52; 72%) were relatively small, with fewer than 100 patients who switched in each study.Table 5Summary of real-world studiesStudyBiosimilar (study name)PopulationPatient number (switch vs. control group)Control group^a^Follow-up duration post switchDiscontinuation rate (switch vs. control group)Dose escalation allowedEtanercept biosimilars Alten et al. 2017a \[[@CR41]\]NSAny1899 vs. 2576NaiveNR10% vs. 9%^b^NR Alten et al. 2017b \[[@CR42]\]NSRheum2938 vs. 1845NaiveNR11%^b^ vs. NRNR De Cock et al. 2017 \[[@CR17]\]SB4RA511^c^No6 months^c^4/29 (14%)^c^NR Dyball et al. 2017 \[[@CR43]\]SB4RA38NoNR6/36 (17%)No Egeberg et al. 2018 \[[@CR44]\]SB4 (DERMBIO)Ps517 (switch + nonswitch)Historical cohort6 monthsHR, 0.46 (95% CI 0.11--1.98; *P *= 0.297)^d^Yes Glintborg et al. 2017a \[[@CR45]\]SB4 (DANBIO)Rheum1623 vs. 407Originator continuers1 year276 (17%) vs. NRYes Hendricks et al. 2017 \[[@CR46]\]SB4Rheum85No8 months7 (8%)NR Rabbitts et al. 2017 \[[@CR47]\]SB4Rheum70 vs. 13Naive4 months5/44 (11%) vs. NRNo Sigurdardottir et al. 2017 \[[@CR48]\]^e^SB4Rheum147No9 months21 (14%)NR Szlumper et al. 2017a \[[@CR49]\]NSPs17No3 monthsNRNR Szlumper et al. 2017b \[[@CR50]\]NSRheum103No7 monthsNRNR Tweehuysen et al. 2017a \[[@CR51]\]SB4 (BIO-SPAN)Rheum625 vs. 600Historical cohort6 months60 (10%) vs. 46 (8%);\
HR, 1.57 (95% CI 1.05--2.36)NRInfliximab biosimilars Abdalla et al. 2017 \[[@CR52]\]CT-P13Rheum34NoMean: 15.8 months5 (15%)NR Akrout et al. 2017 \[[@CR53]\]NSRheum90NoNR14 (16%)Yes Ala et al. 2016 \[[@CR54]\]CT-P13CD20No6 months4 (20%)NR Arguelles-Arias et al. 2017 \[[@CR55], [@CR56]\]CT-P13IBD98 vs. 22Naive^f^12 months12 (12%) vs. NR^f^NR Avouac et al. 2017 \[[@CR57]\]CT-P13IMID260NoMean: 34 weeks59 (23%)NR Babai et al. 2017 \[[@CR58]\]NSSpA53No6 months12 (23%)NR Batticciotto et al. 2016 \[[@CR59]\]CT-P13SpA36No6 months2 (6%)NR Bennett et al. 2016 \[[@CR60]\]CT-P13IBD104No6 months19 (18%)NR Bennucci et al. 2017 \[[@CR61]\]CT-P13SpA41No6 months1 (2%)^g^NR Boone et al. 2017 \[[@CR62]\]NSIBD65No52 weeks8 (12%)NR Boone et al. 2018 \[[@CR63]\]NSIMID125No9 months23 (18%)NR Buer et al. 2017 \[[@CR64]\]CT-P13IBD143No6 months5 (3%)Yes Choe et al. 2017a \[[@CR65]\]CT-P13IBD32 vs. 42Naive30 weeksNRNR Choe et al. 2017b \[[@CR66]\]CT-P13CD204 (switch + naive)Naive30 weeksNRNR Chung et al. 2016 \[[@CR67]\]CT-P13IBD64NoNR7 (11%)NR Dapavo et al. 2016 \[[@CR68]\]CT-P13Ps30 vs. 5NaiveMedian: 23 weeksNRNR De Cock et al. 2017 \[[@CR17]\]CT-P13RA180^c^No6 months^c^11/70 (16%)^c^NR Díaz Hernández et al. 2016 \[[@CR69]\]NSIBD72No6 months3 (4%)NR Eberl et al. 2017 \[[@CR70]\]CT-P13IBD78No16 weeksNRYes Egeberg et al. 2018 \[[@CR44]\]CT-P13 (DERMBIO)Ps296 (switch + nonswitch)Historical cohort2 yearsHR, 1.64 (95% CI, 0.69--3.89; *P *= 0.264)^d^Yes Ellis et al. 2017 \[[@CR71]\]CT-P13RA92 vs. 605Originator continuersMean: 15 months80 (87%) vs. NR^h^NR Farkas et al. 2015 \[[@CR72]\]^e^CT-P13IBD3 vs. 36Naive8 weeks1 (33%) vs. 1 (3%)No Fiorino et al. 2017 \[[@CR73], [@CR74]\]CT-P13 (PROSIT-BIO)IBD97 vs. 450NaiveMean: 6 months5 (5%) vs. 40 (9%)^i^No Forejtová et al. 2017 \[[@CR75]\]CT-P13AS38No6 months1 (3%)NR Geccherle et al. 2017 \[[@CR76]\]CT-P13IBD5 vs. 37Naive^j^6 monthsNRNR Gentileschi et al. 2016 \[[@CR77]\]CT-P13Rheum23NoMean: 1.7 months7 (30%)NR Giunta et al. 2017 \[[@CR78]\]^e^CT-P13Ps46 vs. 17Naive48 weeksNRNo Glintborg et al. 2017b \[[@CR14]\]CT-P13 (DANBIO)Rheum802 vs. 1121Historical cohort1 year132 (16%) vs. NR (14%)\
HR 1.31 (95% CI 1.02--1.68; *P *= 0.03)Yes Gompertz et al. 2017 \[[@CR79]\]^e^CT-P13IBD30No24 weeksNRYes Guerrero Puente et al. 2017 \[[@CR80]\]CT-P13IBD36No12 months4 (11%)Yes Hamanaka et al. 2016 \[[@CR81]\]CT-P13IBD3 vs. 17Naive24 weeks0 vs. 0NR Hlavaty et al. 2016 \[[@CR82]\]CT-P13IBD12 vs. 13Naive56 weeks2 (17%) vs. 3 (23%)Yes Holroyd et al. 2016 \[[@CR83]\]^e^CT-P13Rheum56No5 months4 (7%)NR Huoponen et al. 2017 \[[@CR84]\]CT-P13IBD56No1 yearNRNR Jahnsen et al. 2017 \[[@CR85]\]CT-P13IBD56No6 monthsNRNR Jung et al. 2015 \[[@CR86]\]CT-P13IBD36 vs. 74Naive54 weeks5 (14%) vs. NRYes Kang et al. 2015 \[[@CR87]\]CT-P13IBD9 vs. 8Naive9--66 weeks1 (11%) vs. 0No Kang et al. 2018 \[[@CR88]\]CT-P13IBD38 vs. 36Originator continuers1 year3 (8%) vs. 5 (14%)Yes Kolar et al. 2017 \[[@CR89]\]CT-P13IBD74 vs. 119Naive56 weeks4 (5%) vs. 13 (11%)Yes Malaiya et al. 2016 \[[@CR90]\]^e^CT-P13Rheum30No3 months2 (7%)NR Malpas et al. 2017 \[[@CR91]\]NSRA and axSpA62No3 mo3 (5%)^b^NR Nikiphorou et al. 2015 \[[@CR92]\]CT-P13Rheum39NoMedian: 11 months11 (28%)NR Nugent et al. 2017 \[[@CR93]\]^e^CT-P13\
(EIR SWITCH)IBD35No1 year6 (17%)NR Park et al. 2015 \[[@CR94]\]CT-P13IBD60 vs. 113Naive30 weeksNRYes Phillips et al. 2017 \[[@CR95]\]^e^CT-P13Any136 vs. 1388Originator continuersNR13/1000PY vs. 2/1000PY\
HR 5.53 (95% CI 4.01--7.63)NR Plevris et al. 2017 \[[@CR96]\]CT-P13IBD109NoNRNRYes Presberg et al. 2017 \[[@CR97]\]CT-P13Rheum89NoNR6 (7%)NR Rahmany et al. 2016 \[[@CR98]\]CT-P13IBD78NoNR5 (6%)Yes Ratnakumaran et al. 2017 \[[@CR99]\]CT-P13IBD191 vs. 19Originator continuers12 monthsNRNR Razanskaite et al. 2017 \[[@CR100]\]CT-P13IBD143 vs. 120Historical cohort12 months41 (29%) vs. 31 (26%); *P *= 0.94NR Rubio et al. 2016 \[[@CR101]\]CT-P13Rheum53 vs. 25NaiveMean: 8.3 months5 (9%) vs. 6 (24%)NR Schmitz et al. 2017 \[[@CR102]\]CT-P13Rheum27No12 months7 (26%)NR Schmitz et al. 2018 \[[@CR103]\]CT-P13IBD133No1 year35 (26%)Yes Sheppard et al. 2016 \[[@CR104]\]CT-P13Rheum25NoNR5 (20%)NR Sieczkowska et al. 2016 \[[@CR105]\]CT-P13IBD39NoMean: 8 months15 (38%)Yes Sieczkowska-Golub et al. 2017 \[[@CR106], [@CR107]\]CT-P13CD16No2 years8 (50%)NR Sladek et al. 2017 \[[@CR108]\]CT-P13IBD45No24--36 weeks3 (7%)NR Smits et al. 2017 \[[@CR109], [@CR110]\]CT-P13IBD83No52 weeks15 (18%)Yes Strik et al. 2017 \[[@CR111]\]CT-P13 (SECURE)CD44No16 weeksNRNR Toscano Guzman et al. 2016 \[[@CR112]\]CT-P13UC25No3 monthsNRNR Tweehuysen et al. 2017b \[[@CR15]\]CT-P13 (BIO-SWITCH)Rheum192 vs. 19Originator continuers6 months47 (24%) vs. 1 (5%)NR Van den Hoogen et al. 2016 \[[@CR113]\]CT-P13Rheum136No5 months23 (17%)NR Vergara-Dangond et al. 2017 \[[@CR114]\]CT-P13Rheum7 vs. 6Originator continuers4 cycles1 (14%) vs. 0 ^g^Yes Yazici et al. 2016 \[[@CR115]\]CT-P13RA148 vs. 2870Originator continuersMean: 9 months121 (82%) vs. 1089 (38%)NR*AS* ankylosing spondylitis, *axSpA* axial spondyloarthritis, *CD* Crohn's disease, *CI* confidence interval, *HR* hazard ratio, *IBD* inflammatory bowel disease, *IMID* immune-mediated inflammatory disease, *NR* not reported, *NS* not specified, *Ps* psoriasis, *PY* person-year, *RA* rheumatoid arthritis, *Rheum* rheumatic diseases, *SpA* spondyloarthritis, *TNF* tumor necrosis factor, *UC* ulcerative colitis^a^Naive patients defined as those who received induction therapy with the biosimilar regardless of previous treatment history (including biologic naive, TNF inhibitor naive, and others who may have been previously treated with TNF inhibitors and/or originator product)^b^Switched back to originator, no other discontinuation data provided^c^Study is ongoing, with follow-up data to be captured every 6 months for 3 years and annually thereafter; at time of publication, 6-month data were available for 29 patients taking etanercept biosimilar and for 70 patients taking infliximab biosimilar^d^HR is for patients who were well treated with the originator but switched from originator to biosimilar compared with nonswitchers^e^Publication identified outside the systematic literature search via other sources^f^Data for naive patients were only reported until month 6; at 6 months, discontinuation rates were 7 (7%) for the switch group and 3 (14%) for the control group^g^The only discontinuations reported were those due to adverse events^h^The authors are unclear which of the two discontinuation rates (19% or 34%) listed by the publication for the originator continuer control group was accurate^i^The only discontinuation rates reported were those due to serious adverse events or infusion reactions^j^Switch group consisted of patients with ≥ 12 months of clinical remission; control group consisted of anti-TNF-naive patients, infliximab-naive patients, and patients previously treated with infliximab Table 6Characteristics and design elements of published real-world evidence studiesStudyRandomized at time of switchComparison group^a^Powered to detect differences in efficacy after switchMultiple switchImmunogenicity data reportedFollow-up ≥ 12 monthsIndividual patient-level outcomes^b^ reportedEtanercept biosimilars Alten et al. 2017a \[[@CR41]\]NoNoNoNoNoNRNo Alten et al. 2017b \[[@CR42]\]NoNoNoNoNoNRNo De Cock et al. 2017 \[[@CR17]\]NoNoNoNoNoNoNo Dyball et al. 2017 \[[@CR43]\]NoNoNoNoNoNRNo^c^ Egeberg et al. 2018 \[[@CR44]\]NoYesNoNoNoNoNo Glintborg et al. 2017a \[[@CR45]\]NoYesNoNoNoYesNo Hendricks et al. 2017 \[[@CR46]\]NoNoNoNoNoNoNo Rabbitts et al. 2017 \[[@CR47]\]NoNoNoNoNoNoNo Sigurdardottir et al. 2017 \[[@CR48]\]NoNoNoNoNoNoNo Szlumper et al. 2017a \[[@CR49]\]NoNoNoNoNoNoNo Szlumper et al. 2017b \[[@CR50]\]NoNoNoNoNoNoNo Tweehuysen et al. 2017a \[[@CR51]\]NoYesNoNoNoNoNo^c^Infliximab biosimilars Abdalla et al. 2017 \[[@CR52]\]NoNoNoNoNoYesNo^c^ Akrout et al. 2017 \[[@CR53]\]NoNoNoNoNoNRNo Ala et al. 2016 \[[@CR54]\]NoNoNoNoNoNoNo^c^ Arguelles-Arias et al. 2017 \[[@CR55], [@CR56]\]NoNoNoNoNoYesNo^c^ Avouac et al. 2017 \[[@CR57]\]NoNoNoNoNoNoNo^c^ Babai et al. 2017 \[[@CR58]\]NoNoNoNoNoNoNo Batticciotto et al. 2016 \[[@CR59]\]NoNoNoNoNoNoNo^c^ Bennett et al. 2016 \[[@CR60]\]NoNoNoNoYesNoNo Bennucci et al. 2017 \[[@CR61]\]NoNoNoNoYesNoNo^c^ Boone et al. 2017 \[[@CR62]\]NoNoNoNoYesYesNo Boone et al. 2018 \[[@CR63]\]NoNoNoNoYesNoNo Buer et al. 2017 \[[@CR64]\]NoNoNoNoYesNoNo^c^ Choe et al. 2017a \[[@CR65]\]NoNoNoNoNoNoNo Choe et al. 2017b \[[@CR66]\]NoNoNoNoNoNoNo Chung et al. 2016 \[[@CR67]\]NoNoNoNoNoNRNo Dapavo et al. 2016 \[[@CR68]\]NoNoNoNoNoNoNo De Cock et al. 2017 \[[@CR17]\]NoNoNoNoNoNoNo Díaz Hernández et al. 2016 \[[@CR69]\]NoNoNoNoNoNoNo^c^ Eberl et al. 2017 \[[@CR70]\]NoNoNoNoYesNoNo^c^ Egeberg et al. 2018 \[[@CR44]\]NoYesNoNoNoYesNo Ellis et al. 2017 \[[@CR71]\]NoYesNoNoNoYesNo Farkas et al. 2015 \[[@CR72]\]NoNoNoNoYesNoNo^c^ Fiorino et al. 2017 \[[@CR73], [@CR74]\]NoNoNoNoYesNoNo^c^ Forejtová et al. 2017 \[[@CR75]\]NoNoNoNoNoNoNo^c^ Geccherle et al. 2017 \[[@CR76]\]NoNoNoNoNoNoNo Gentileschi et al. 2016 \[[@CR77]\]NoNoNoNoNoNoNo Giunta et al. 2017 \[[@CR78]\]NoNoNoNoNoNoNo^c^ Glintborg et al. 2017b \[[@CR14]\]NoYesNoNoNoYesNo^c^ Gompertz et al. 2017 \[[@CR79]\]NoNoNoNoYesNoNo Guerrero Puente et al. 2017 \[[@CR80]\]NoNoNoNoYesYesNo^c^ Hamanaka et al. 2016 \[[@CR81]\]NoNoNoNoNoNoNo^c^ Hlavaty et al. 2016 \[[@CR82]\]NoNoNoNoNoYesNo^c^ Holroyd et al. 2016 \[[@CR83]\]NoNoNoNoNoNoNo^c^ Huoponen et al. 2017 \[[@CR84]\]NoNoNoNoNoYesNo^c^ Jahnsen et al. 2017 \[[@CR85]\]NoNoNoNoNoNoNo^c^ Jung et al. 2015 \[[@CR86]\]NoNoNoNoNoYesNo^c^ Kang et al. 2015 \[[@CR87]\]NoNoNoNoNoYesNo^c^ Kang et al. 2018 \[[@CR88]\]NoYesNoNoYesYesNo^c^ Kolar et al. 2017 \[[@CR89]\]NoNoNoNoYesYesNo^c^ Malaiya et al. 2016 \[[@CR90]\]NoNoNoNoNoNoNo^c^ Malpas et al. 2017 \[[@CR91]\]NoNoNoNoNoNoNo^c^ Nikiphorou et al. 2015 \[[@CR92]\]NoNoNoNoYesNoNo^c^ Nugent et al. 2017 \[[@CR93]\]NoNoNoNoYesYesNo Park et al. 2015 \[[@CR94]\]NoNoNoNoNoNoNo^c^ Phillips et al. 2017 \[[@CR95]\]NoYesNoNoNoNRNo Plevris et al. 2017 \[[@CR96]\]NoNoNoNoYesNRNo Presberg et al. 2017 \[[@CR97]\]NoNoNoNoYesNRNo^c^ Rahmany et al. 2016 \[[@CR98]\]NoNoNoNoNoNRNo^c^ Ratnakumaran et al. 2017 \[[@CR99]\]NoYesNoNoYesYesNo Razanskaite et al. 2017 \[[@CR100]\]NoYesNoNoYesYesNo^c^ Rubio et al. 2016 \[[@CR101]\]NoNoNoNoNoNoNo Schmitz et al. 2017 \[[@CR102]\]NoNoNoNoYesYesYes^c^ Schmitz et al. 2018 \[[@CR103]\]NoNoNoNoYesYesYes Sheppard et al. 2016 \[[@CR104]\]NoNoNoNoNoNRNo Sieczkowska et al. 2016 \[[@CR105]\]NoNoNoNoNoNoNo^c^ Sieczkowska-Golub et al. 2017 \[[@CR106], [@CR107]\]NoNoNoNoYesYesNo^c^ Sladek et al. 2017 \[[@CR108]\]NoNoNoNoYesNoNo Smits et al. 2017 \[[@CR109], [@CR110]\]NoNoNoNoYesYesYes^c^ Strik et al. 2017 \[[@CR111]\]NoNoNoNoYesNoNo^c^ Toscano Guzman et al. 2016 \[[@CR112]\]NoNoNoNoNoNoNo Tweehuysen et al. 2017b \[[@CR15]\]NoYesNoNoYesNoNo^c^ Van den Hoogen et al. 2016 \[[@CR113]\]NoNoNoNoNoNoNo Vergara-Dangond et al. 2017 \[[@CR114]\]NoYesNoNoNoNRNo^c^ Yazici et al. 2016 \[[@CR115]\]NoYesNoNoNoNoNo^a^Excludes comparison group consisting of naive patients or patients previously treated with other biologics^b^Individual patient-level data defined as individual data points that included, but were not limited to, immunogenicity markers that were separately reported for each individual participant in the publication of a clinical study; data reported separately for each individual study participant may also have included, for example, demographic characteristics, efficacy outcomes, and/or laboratory test results^c^Reports patient-reported outcome measures

Similar to the RCTs, and as anticipated, none of the RWE studies fulfilled all the design elements for a robust switching study (Tables [2](#Tab2){ref-type="table"}, [6](#Tab6){ref-type="table"}). All of the RWE studies investigated a single switch from originator therapy to its biosimilar, and none were randomized at the time of the switch (Fig. [4](#Fig4){ref-type="fig"}b). However, 26 (35%) studies did report a switch-back from biosimilar to originator therapy among patients who had reported worsened outcomes or who had requested to switch back to the originator therapy for other reasons \[[@CR15], [@CR17], [@CR41]--[@CR43], [@CR46], [@CR48], [@CR51], [@CR52], [@CR57], [@CR58], [@CR63], [@CR71], [@CR75], [@CR77], [@CR83], [@CR86], [@CR90]--[@CR92], [@CR95], [@CR100], [@CR103], [@CR104], [@CR113], [@CR115]\]. Furthermore, most studies did not report whether they were powered to detect differences in efficacy or safety after the switch, although several multiple cohort studies did provide some statistical comparisons, albeit with divergent results \[[@CR14], [@CR44], [@CR45], [@CR51], [@CR73], [@CR88], [@CR95], [@CR99], [@CR100], [@CR115]\]. Twenty-five (34%) studies reported immunogenicity data, and three (4%) studies reported individual patient-level immunogenicity outcomes. In the 65 (88%) studies that reported follow-up duration post switch, follow-up duration ranged from 1.7 months to 2 years (Table [5](#Tab5){ref-type="table"} and Fig. [3](#Fig3){ref-type="fig"}b), with only 21 studies (32%) following patients post switch for ≥ 12 months (Table [6](#Tab6){ref-type="table"}).

Discontinuation Rate Post Switch in Randomized Controlled Trials {#Sec7}
----------------------------------------------------------------

Of the 17 RCTs, discontinuation rates were reported for 12 (71%) studies (Fig. [5](#Fig5){ref-type="fig"}). Overall discontinuation rates ranged from 5% to 33% in the switch groups and from 4% to 18% in the comparison groups (Table [3](#Tab3){ref-type="table"}). In general, discontinuation rates were divergent; they were slightly numerically higher among the switchers in some studies and higher in the control group in other studies. Most notably, the discontinuation rate demonstrated for the switch group in the Tanaka et al. study (33%) was considerably higher than that for the continuers group (16%) \[[@CR37]\].Fig. 5Patient discontinuation rates reported in published RCTs reporting non-medical switching from TNF inhibitor originator to biosimilar. *RCT* randomized controlled trial, *TNF* tumor necrosis factor

Discontinuation Rate Post Switch in Real-World Evidence Studies {#Sec8}
---------------------------------------------------------------

In the 74 RWE studies, discontinuation rates in the switch groups showed greater variation compared with those rates in the RCTs, ranging from 0% to 87% in the infliximab studies and from 8% to 17% in the etanercept studies (Table [5](#Tab5){ref-type="table"} and Fig. [6](#Fig6){ref-type="fig"}). Discontinuation rates were similarly variable across studies regardless of the patient population (gastroenterology, 0--50%; rheumatology, 3--87%). Only 8 (11%) studies (5 in rheumatologic conditions, 2 in IBDs, and 1 in multiple indications) compared overall raw discontinuation rates between the switch group and the historical/parallel originator continuer group, with divergent results \[[@CR14], [@CR15], [@CR51], [@CR71], [@CR88], [@CR95], [@CR100], [@CR115]\]. In three studies, discontinuation rates were slightly numerically lower for continuers versus switchers (8% vs. 10% \[[@CR51]\], 14% vs. 16% \[[@CR14]\], and 26% vs. 29% \[[@CR100]\], respectively), whereas in one study discontinuation rates were slightly numerically higher for continuers versus switchers (14% vs. 8% \[[@CR88]\]). In contrast, in four studies, the differences between the continuer and switcher groups were more pronounced (34% vs. 87% \[[@CR71]\], 2 vs. 13 per 1000 patient-years \[[@CR95]\], 5% vs. 24% \[[@CR15]\], and 38% vs. 82% \[[@CR115]\]). In three studies, hazard ratios showed that patients who switched from an originator to its biosimilar were significantly more likely to discontinue treatment than the historical/parallel continuer cohorts \[[@CR14], [@CR51], [@CR95]\], whereas similar analyses in two studies showed no significant differences (Table [5](#Tab5){ref-type="table"}) \[[@CR44], [@CR100]\].Fig. 6Patient discontinuation rates reported in published RWE studies reporting non-medical switching from TNF inhibitor originator to biosimilar. *NR* not reported; *RWE* real-world evidence; *TNF* tumor necrosis factor. ^a^Of the 74 RWE studies, 51 reported discontinuation rates. Etanercept-biosimilar and infliximab-biosimilar aspects of the De Cock et al. study \[[@CR17]\] are each displayed separately. ^b^Control group consisted of naive patients (defined as those who received induction therapy with the biosimilar regardless of previous treatment history, including biologic naive, TNF-inhibitor naive, and others who may have been previously treated with TNF inhibitors and/or originator product). ^c^Control group consisted of originator continuers. ^d^Control group consisted of historical cohort. ^e^The authors are unclear which of the two discontinuation rates (19% or 34%) listed by the publication for the originator continuer control group was accurate

Similarly, only six (8%) studies compared overall discontinuation rates between switch and treatment-naive groups \[[@CR72], [@CR81], [@CR82], [@CR87], [@CR89], [@CR101]\]. In three studies, rates were higher for the naive group versus switchers (23% vs. 17% \[[@CR82]\], 11% vs. 5% \[[@CR89]\], and 24% vs. 9% \[[@CR101]\]), whereas in two studies rates were lower for the naive group versus switchers and differences between the groups were more pronounced (3% vs. 33% \[[@CR72]\] and 0% vs. 11% \[[@CR87]\]); however, the numbers of patients in these studies were small (Table [5](#Tab5){ref-type="table"}). In one study, discontinuation rates were 0% for both groups \[[@CR81]\].

Discussion {#Sec9}
==========

This systematic review assessed the robustness and conclusiveness of the current evidence of non-medical switching from an originator TNF inhibitor to its biosimilar as reported in RCTs and RWE studies published between 1 January 2012 and 14 February 2018. The results of this review confirm that, when assessing the totality of the evidence, no single non-medical switching RCT or RWE study has been identified in which all seven key design elements of a robust switching study have been comprehensively incorporated and analyzed. Furthermore, among the 91 studies (98 publications) identified, discontinuation rates varied widely, suggesting that the current evidence is inconclusive and that more data from properly designed studies are needed to bridge the knowledge gap.

Switching from originator biologic therapies to their biosimilars is becoming more attractive because of the potential cost savings \[[@CR3], [@CR4]\]. However, caution is needed when switching patients who are stable on their current therapy. A recent systematic review of 29 US-based studies (each ≥ 25 patients) examining a total of 253,795 patients treated with a variety of medications (e.g., TNF inhibitors, antihypertensives, antidepressants, insulin, and statins) demonstrated that negative or neutral effects were more commonly associated with non-medical switching than positive effects \[[@CR116]\], an observation that was especially apparent among stable patients with well-controlled disease. Thus, more robust studies are needed to assess the outcomes of non-medical switching, particularly on an individual patient level. The results of this systematic review support this concept and demonstrate that the current evidence on the safety and efficacy of non-medical switching from the originator biologic to its biosimilar is inconclusive and inconsistent. In general, non-medical switching evidence should come from long-term, randomized, controlled, adequately powered studies that use multiple switches between the originator and its biosimilar (Table [2](#Tab2){ref-type="table"}) \[[@CR3], [@CR10]\]. In addition to safety and efficacy outcomes, these studies should collect immunogenicity and individual patient-level outcomes.

Although the RCTs and RWE studies conducted to date fulfill some of these requirements and provide valuable information on safety and efficacy consequences after non-medical switching, several additional factors need to be considered when analyzing the totality of the evidence. First, although most of the identified RCTs were powered to detect differences in efficacy and safety during the head-to-head comparison phase of originator versus biosimilar, none were powered to detect these differences after the switch from originator to biosimilar. The only exception to this was the NOR-SWITCH study, which, as highlighted above, was powered at a pooled, but not individual, indication level to compare rates of disease worsening between switchers and continuers \[[@CR16]\]; in addition to the pooling of indications, the NOR-SWITCH study had several other important methodologic limitations that have been examined elsewhere \[[@CR19]\]. Second, although all RCTs included a comparison group, only 11 (65%) studies followed a group of randomized patients continuing on the originator \[[@CR16], [@CR22], [@CR23], [@CR25]--[@CR29], [@CR31]--[@CR34], [@CR36], [@CR39]\], and only 3 (18%) studies (ADACCESS \[[@CR22]\], EGALITY \[[@CR31], [@CR32]\], and ARABESC-OLE \[[@CR25]\]) investigated multiple switches between the originator and its biosimilar. Finally, the current publications for most of the RCTs lacked long-term follow-up data and all lacked individual patient-level data.

At the time of this review, the bulk of the non-medical switching evidence comes from RWE studies (particularly among patients switching from infliximab originator to biosimilar) and, although they play an important role in the continuous evaluation of therapies such as biosimilars, RWE studies should not supersede well-designed RCTs in the investigation of non-medical switching from an originator to its biosimilar \[[@CR3], [@CR10], [@CR117]\]. Similar to the RCTs and as anticipated, none of the currently published RWE studies met all of the design elements for a robust switching study; the patient populations were generally small and widely heterogeneous, the follow-up periods were mostly short, and most studies lacked control groups and immunogenicity and/or individual patient-level analyses. Furthermore, although some of the multiple-cohort RWE studies provided some statistical comparisons \[[@CR14], [@CR44], [@CR45], [@CR51], [@CR73], [@CR88], [@CR95], [@CR99], [@CR100], [@CR115]\], none of them were powered to detect differences in efficacy or safety after the switch.

The diverse outcomes observed across the RCTs and RWE studies are most likely a consequence of the variability of the study designs as well as a lack of the seven key design elements. This was evident in particular across the RWE studies that included elements such as grouping of indications, enrolling heterogeneous patient populations that varied in duration of disease and time on current therapy, and mixing treatment-naive and stable patient populations while lacking other elements such as defining disease stability pre-switch, identifying concomitant medications pre- and post switch, and describing dose intensification details post switch. These are typical characteristics for RWE studies; however, because of the heterogeneous results across the studies, the data need to be assessed with caution, especially for decision-making purposes.

To assess the consistency of the current non-medical switching data across studies, we examined the post-switch rates of therapy discontinuation across studies. Discontinuation data can provide a marker of treatment efficacy and tolerability and can also provide insight into clinical and patient-reported consequences of non-medical switching \[[@CR118]\]. The overall discontinuation rates in the RCTs ranged from 5% to 33% in the switch groups, with even larger variation noted among the RWE studies (0--87%). This high level of variation is concerning, especially when considering that some studies included non-medically switched patients with chronic diseases who may have been in long-term disease remission before the switch. Although discontinuation rates were the only outcome examined here, outcomes reported by the RCTs are also limited in that they did not perform statistical analyses on switch groups. Of the RCT non-medical switching studies published to date, only ADACCESS, EGALITY, and NOR-SWITCH performed statistical analyses on switch groups rather than simply reporting descriptive numerical data. Future studies should evaluate in more detail the specific reasons for, as well as consequences of, therapy discontinuation following a non-medical switch from an originator to its biosimilar.

As the US regulatory guidance currently stands, FDA approvals of biosimilars are entirely based on head-to-head trials versus the originator. However, depending on the clinical experience, additional evaluation(s) may be needed in certain patient subgroups to assess potential risks in terms of immunogenicity, hypersensitivity, or other reactions that may arise following a single switch from originator to the proposed biosimilar product \[[@CR119]\]. Therefore, owing to the limited, inconclusive, and heterogeneous nature of the currently available data, non-medical switching from an originator to a biosimilar not designated as interchangeable in the USA should be an evidence-based decision made between the physician and the patient \[[@CR120]\]. Currently, no biosimilar has yet been deemed interchangeable with its originator product in the USA \[[@CR11]\], but this may change in the future and at least one trial with the apparent objective of demonstrating interchangeability with the originator adalimumab has already commenced: the VOLTAIRE-X study with BI 695501 \[[@CR121], [@CR122]\].

Based on the current literature, the amount of data describing switching from infliximab to CT-P13 by far outweighs the amount of data for any other originator-biosimilar pair, but it is important to note that these data should not be transferred to other biosimilars. With increasing numbers of biosimilars coming to market for each originator product, it is likely that switching will also occur between multiple biosimilars of the same originator product and that individual patients will experience multiple switches. Because biosimilars are evaluated against the originator product but not against other biosimilars, any similarity between two biosimilars of the same originator product is unknown \[[@CR123]\]. Currently, and to the best of the authors' knowledge, no studies have been published that primarily examine the consequences of switching between different biosimilars of the same originator product. Furthermore, none of the RWE studies published to date have examined multiple switches between an originator and its biosimilar. Therefore, further research is needed to evaluate patient efficacy, safety, and immunogenicity after multiple switches or when switching between different individual biosimilars of the same originator. These data should come from well-controlled clinical trials, as suggested by the FDA, and not solely from registry studies \[[@CR117]\].

In this systematic review, the use of discontinuation rates as an outcome, especially in the RWE studies, is limited by the fact that discontinuation rates are cumulative and all of the RWE studies varied in length. Other limitations included potential publication bias, limited focus on secondary outcomes that were included in some trials (such as quality-of-life assessments), and variability in the methodology used by individual studies. In addition, many of the studies were descriptive in nature and were not powered or designed to detect differences post switch; as a result, it was not possible to pool the studies for a meta-analysis of either safety or efficacy end points. Finally, the proposed benchmark of seven key study design elements is limited by having been derived from regulatory requirements and expert opinion rather than all possible elements of study design that might have bearing on non-medical switching, for reasons of practicality.

Conclusions {#Sec10}
===========

Based on the totality of the published data and the prevailing evidence gaps, conclusive safety and efficacy of non-medical switching from an originator TNF inhibitor therapy to its biosimilar has yet to be fully demonstrated. To properly assess the safety and efficacy of non-medical switching, future studies should incorporate all of the seven key study design elements discussed in this review. Furthermore, systematic collection of switching data using validated registries and medical records is essential to gather the totality of clinical evidence needed to inform clinical decision-making on the safety and efficacy of non-medical switching from an originator to a biosimilar. In parallel, continued pharmacovigilance is important to identify and monitor rare and long-term safety events. Overall, in patients who are doing well on their current biologic treatment, such as TNF inhibitors, switching for non-medical reasons should be approached with caution, as data describing non-medical switching for currently marketed biosimilars are not robust and are inconclusive regarding any potential impact on efficacy, safety, and immunogenicity, particularly at the individual patient level. Decisions to switch should remain between the treating physician and the patient and be made on a case-by-case basis relying on scientific evidence.
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